WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES

Checking

 

CSL Limited CSL

ASXPharmaceuticalsFinancials to Jun 30, 2026 · Updated Nov 11, 2026

On Stock Analysis · affiliate link
CSL financials
Moat score
79
ROIC
-13.2%
P/E
–
Incl. −$6.0B one-offs
EV/EBIT
–
Incl. −$7.9B one-offs
FCF yield
3.4%
Dividend yield
2.1%
Market cap
$66.6B

Moat ranks

Score rankTied #157 of 396
Durabilitydurable
Market structureOligopoly
Pricing powermoderate

Balance sheet

6/30/26
$BJun '25Jun '26
Cash2.21.5
Securities0.00.0
Debt9.89.4
Net cash-7.7-7.9
Equity19.314.8
Leverage
Debt / EBITDA
–
Debt / equity
0.63×
Leases (6/30/26)
$1.5B
Capital
Diluted shares
482M
Book value / share
$30.70
Price / book
4.5×
Net cash / share
−$16.33
Market cap
$66.6B
Enterprise value
$74.4B

Per-share record

Fiscal years and TTM
Scale
$0$10$20$30$40'17'18'19'20'21'22'23'24'2532.78'26
Revenue per shareCash flow per share

Key indicators

Latest: H2 '26
IndicatorLatestVs year agoLast 8 halves
Revenue growth5.5%+0.7 pts
Operating margin-57.1%-76.4 pts
FCF margin21.3%-4.7 pts
Capex / revenue8.3%+1.7 pts
Immunoglobulin sales$6.2B+3%
Behring segment gross profit$5.6B+0%
Donor satisfaction88.0%––
Pandemic reservation fees$183M+2%
Seasonal influenza vaccine sales$1.6B––

Margins and growth from reported quarters; company KPIs as reported in results releases.

About CSL

CSL makes medicines from donated plasma, influenza vaccines and iron and kidney-disease treatments. Behring supplies most revenue and has an established collection and manufacturing chain.

Revenue mix
CSL Behring 72.1%CSL Vifor 15.1%CSL Seqirus 12.9%
  • Supply Chain Control

    Controlling plasma collection, fractionation and distribution helps CSL secure supply and trace quality from donor to patient.

  • Physical Network Density

    A dispersed collection network gives donors local access and takes time to replicate.

  • Government Contracting Relationships

    Established preparedness contracts and qualified influenza plants make CSL a repeat supplier to governments.

Timeline
  1. Oct 26, 2026

    CSL named Gordon Naylor as its next chair from 31 March 2027, when Brian McNamee will retire. Carolyn Hewson will become senior independent director.

  2. Oct 22, 2026

    CSL disclosed a Victorian Supreme Court group proceeding concerning its FY2026 disclosures and outlook. CSL denies liability and says it will defend the case.

  3. Oct 21, 2026

    CSL named former ViiV Healthcare CEO Deborah Waterhouse as its next CEO, effective 1 February 2027. Gordon Naylor remains interim CEO until then.

  4. Oct 8, 2026

    CSL agreed to switch its US plasma collection centres to Haemonetics’ latest platform, with rollout expected by the end of 2027. Terumo will support the transition from its Rika system.

  5. Oct 5, 2026

    CSL agreed to pay Alentis US$355 million upfront and fund specified lixudebart trials for a 55% share of eventual global profits, adding a potential kidney and liver treatment with clinical and funding risk.

Financial record

Fiscal year2017201820192020202120222023202420252026TrendChange 2017–26
Per share ($)
Revenue15.2217.4418.8120.0822.6022.4727.5130.5032.0032.78+8.9%/yr
Cash flow2.734.193.625.467.945.595.385.707.327.29+11.5%/yr
Earnings2.933.814.234.615.214.804.535.456.17-5.35–
Free cash flow0.852.000.792.464.282.941.883.115.274.64+20.8%/yr
Capex1.892.192.833.003.652.653.502.592.052.65+3.9%/yr
Dividends1.321.481.781.942.102.212.242.462.742.93+9.3%/yr
Book value6.938.9911.5714.3318.3731.0132.6235.7939.7730.70+18.0%/yr
Diluted shares (M)456454454456456470484485486482+0.6%/yr
Totals ($B)
Revenue6.97.98.59.210.310.613.314.815.615.8+9.6%/yr
Operating income1.82.42.52.73.12.93.13.84.1-3.7–
Net income1.31.71.92.12.42.32.22.63.0-2.6–
Free cash flow0.40.90.41.12.01.40.91.52.62.2+21.5%/yr
Buybacks0.30.10.00.00.00.00.00.00.00.7+9.7%/yr
Dividends0.60.70.80.91.01.01.11.21.31.4+9.9%/yr
Net cash-3.1-3.5-4.0-3.8-2.82.2-9.0-8.9-7.7-7.9−$4.8B
Margins & returns (%)
Gross margin52.155.456.057.156.754.351.351.851.951.1-1.0 pts
Operating margin25.530.129.329.730.427.723.125.826.6-23.3-48.8 pts
Net margin19.321.822.523.023.021.316.517.919.3-16.3-35.6 pts
FCF margin5.611.54.212.219.013.16.810.216.514.1+8.6 pts
ROIC22.925.322.021.422.719.110.011.812.4-13.2-36.0 pts
Return on equity42.342.436.532.228.315.513.915.215.5-17.4-59.7 pts
R&D % of revenue9.68.99.710.19.710.99.59.78.77.7-1.9 pts
Stock pay % of revenue0.20.40.60.90.91.11.01.11.01.1+0.9 pts
Capex % of revenue12.412.515.014.916.211.812.78.56.48.1-4.3 pts

Change uses 2017 and 2026 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2017 base. Trend shows the fiscal years.

Per-share values use diluted weighted shares.ROIC = operating income × (1 − 18.9% tax rate, the company's own over three fiscal years excluding one-offs) ÷ (equity + debt − cash and current securities). Returns show a dash when their base is negative or under 10% of revenue. Free cash flow = operating cash flow − capex. Debt is all borrowings; net cash counts long-term securities and excludes leases. No trailing-twelve-month column: no complete four quarters end after the last fiscal year.

Moat

Moat scorecard

Moat score79
Strength
Confidence
Structure
Oligopoly
Durability
durable
Trajectory
stable
Pricing power
moderate
Segments
  • CSL Behring72.1%
    2 claims
  • CSL Seqirus12.9%
    1 claim
  • CSL Vifor15.1%
    Not scored: evidence insufficient

Moat claims

Applies to
CSL Behring
Confidence
Durability
durable
Trajectory
stableas of Jun 30, 2026
Why it holds

Controlling plasma collection, fractionation and distribution helps CSL secure supply and trace quality from donor to patient. Replicating the chain takes capital and validated manufacturing processes. It protects CSL against smaller entrants; Takeda and Grifols already operate integrated systems.

Why stable

FY2026 immunoglobulin sales were US$6.248 billion and flat at constant currency; collection cost per litre continued to fall, but Horizon 2 still needs clinical evidence before its yield advantage can reach patients.

Indicators
  • Immunoglobulin sales$6.2B+3%
  • Behring segment gross profit$5.6B+0%
Risks
  • Rivals expand donor networks and fractionation capacity, increasing competition for inputs and tenders.
  • Donor fees, labour costs or collection restrictions raise the cost of the critical input.
  • Reimbursement cuts and non-plasma alternatives reduce the revenue earned from each litre.
  • Horizon 2 approval or construction takes longer than planned.

Profile change log

  1. Nov 10, 2026 · business change

    CSL named Gordon Naylor as its next chair from 31 March 2027, when Brian McNamee will retire. Carolyn Hewson will become senior independent director.

  2. Nov 10, 2026 · business change

    CSL disclosed a Victorian Supreme Court group proceeding concerning its FY2026 disclosures and outlook. CSL denies liability and says it will defend the case.

  3. Nov 10, 2026 · business change

    CSL named former ViiV Healthcare CEO Deborah Waterhouse as its next CEO, effective 1 February 2027. Gordon Naylor remains interim CEO until then.

  4. Nov 10, 2026 · business change

    CSL agreed to switch its US plasma collection centres to Haemonetics’ latest platform, with rollout expected by the end of 2027. Terumo will support the transition from its Rika system.

  5. Oct 6, 2026 · business change

    CSL agreed to pay Alentis US$355 million upfront and fund specified lixudebart trials for a 55% share of eventual global profits, adding a potential kidney and liver treatment with clinical and funding risk.

  6. Oct 6, 2026 · business change

    CSL disclosed US$7.923 billion of FY2026 restructuring and impairment expenses, a US$2.579 billion shareholder loss and expected Vifor revenue decline of about 25% in FY2027. The reset confirms weaker returns on acquired drugs and some manufacturing assets.

  7. Oct 6, 2026 · business change

    The European Commission revoked Tavneos authorisation after the supporting trial proved unreliable, removing a Vifor renal medicine from EU markets.

  8. Oct 6, 2026 · business change

    CSL announced Horizon 2 clinical work expected to start in mid-2027 after regulator discussions, leaving its next major plasma-yield improvement dependent on additional clinical evidence.

  9. Oct 6, 2026 · business change

    Gordon Naylor became interim CEO after Paul McKenzie retired, placing the restructuring and commercial recovery under new leadership.

  10. Oct 6, 2026 · business change

    CSL sold the Ruide Chinese plasma business for US$185 million, reducing its directly owned local collection and fractionation footprint.

  11. Oct 6, 2026 · business change

    CSL completed the Vifor acquisition, adding iron and renal medicines and a minority-owned dialysis partnership. FY2023 therefore includes a larger business than FY2022.

  12. Oct 6, 2026 · analyst revision

    All three moat claims now have current evidence and stable trajectories. Vifor has insufficient evidence for a segment-wide moat after the sourced generic, reimbursement and regulatory losses. The debate, interim management and linked market profiles now explain these limits.

  13. Oct 6, 2026 · analyst revision

    Segment profit shares were removed because central costs are excluded from segment results. The plasma-network claim was reduced from strength 4 and confidence 4 to 3 and 3: current evidence supports a useful footprint, without verified dominant local density or a peer unit-cost advantage.

Industry & peers

Peer map

0%10%20%30%40%50%60708090100Moat scoreIndustry medianCSL
No peer numbers yet

Peers appear on the map as their numbers are collected.

Global plasma-derived therapies

As of Oct 6, 2026
OligopolyLow cyclicality

Medicines fractionated from donated human plasma, including immunoglobulins, albumin, coagulation factors and specialty proteins. This excludes recombinant proteins, monoclonal antibodies and gene therapies; those also contribute to CSL Behring revenue.

  1. CSL Behring
  2. Grifols
  3. Takeda
  4. Octapharma
StocksMoatGross m.Op. m.
CSL7951.1%-23.3%
Industry median176973.1%21.8%
Sector median557661.5%17.3%
All stocks median3987653.1%20.0%

Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.

Drivers & risks

Demand drivers
  • Long-term immune replacement and neurological treatment create repeat demand. Better diagnosis expands the treated population even in a weak economy.
  • Home subcutaneous administration and more convenient dosing can improve uptake and retain patients, if clinical results and reimbursement remain competitive.
  • Faster collection and higher protein yield can increase output from a scarce biological input. Manufacturing validation determines when a process improvement becomes saleable supply.
  • Insurance access and hospital budgets determine how unmet medical need becomes orders. Emerging-market access can expand volumes while lowering realised prices.
Risks
  • Paid US donors are a concentrated input source. Competition for donors, wage inflation, collection restrictions and public-health interruptions can raise cost or reduce supply.
  • New fractionation capacity from established rivals can increase tender competition. Other integrated producers already possess the main collection and manufacturing capabilities.
  • Non-plasma therapies can replace immunoglobulin in some neurological indications and reduce demand growth for particular products.
  • US reimbursement changes and Chinese albumin cost controls can cut realised price and channel orders even when underlying patient need is stable.
  • Regulatory approvals, quality failures and cold-chain interruptions can delay output. Currency translation is material for global producers; higher financing and energy costs increase the cash needed to expand plants.

Bulls & bears

Key question · as of Oct 6, 2026

Can Behring restore profitable plasma growth fast enough to offset Vifor decline and fund new manufacturing and drug development without another large loss of invested capital?

Arguments

4 forFaded: weakening or settled4 against

What to watch

  1. 1Immunoglobulin revenue, underlying patient demand and channel inventory
  2. 2Behring segment gross profit, reported cost per litre and manufacturing yield
  3. 3Iron and nephrology revenue after Velphoro reimbursement expiry
  4. 4Operating cash flow, PPE and intangible-asset cash spending
  5. 5Horizon 2 trial and approval milestones, and lixudebart trial results

Next check: 10 February 2027 half-year results for plasma recovery and the first outlook after Velphoro TDAPA expiry.

Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.

Cite or reuse this data

Free to reuse, commercially too, with a credit link. See the data license.

Moat Score 79/100 by <a href="https://www.findmymoat.com/stocks/XASX:CSL">Find My Moat</a> (as of September 2026)

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.